TransCode Therapeutics Reports Positive Data from First-in-H

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data

Related Keywords

Boston , Massachusetts , United States , Tania Montgomery Hammon , Daniel Vlock , Zdravka Medarova , Exchange Commission , Transcode Therapeutics Inc , Business Development , Nasdaq , Code Therapeutics , Chief Scientific Officer , Chief Medical , Private Securities Litigation Reform Act , Investigational New Drug , Annual Report ,